Cell and Gene Therapy Insights Webinar: evaluating endonucleases in your AAV process

Making robust choices: evaluating materials in your AAV process

Webinar presenter: Michael Bodo, Upstream Process Development Scientist at Spark Therapeutics 

Wednesday June 18th 2025
08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST
 

Endonucleases play a fundamental role in AAV production, though introducing novel materials into existing AAV processes can present risks. In this webinar, we will present a structured framework to assess the impact and benefits of integrating new materials like novel endonucleases into established AAV manufacturing workflows. Key evaluation criteria for new AAV manufacturing materials will also be explored. 
 

Attendees will see comparative performance case study data of market endonucleases, focusing on critical quality attributes (CQAs) such as viral titer and residual host cell and plasmid DNA. Learn about the evaluation and potential integration of a new endonuclease into an existing AAV purification process.  
 

• See data comparing the EndoCleave with another WT endonuclease expressed in E. coli, highlighting its impact on CQAs relevant to material selection, such as titer and residual DNA levels 
  
  
• Learn strategies to thoroughly assess the compatibility, performance, and cost-effectiveness of new materials, process steps, and solutions before full-scale implementation, minimizing potential disruptions 
  
  
• Gain an understanding of critical parameters to consider when assessing the suitability of new materials for your existing AAV processes